Skin bacterial infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Skin bacterial infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of single-dose oritavancin safety and tolerability in children with acute bacterial skin and skin structure infections https://clinicaltrials.eu/trial/study-on-the-safety-of-oritavancin-for-treating-children-with-acute-bacterial-skin-infections/ Wed, 29 Apr 2026 15:01:54 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-oritavancin-for-treating-children-with-acute-bacterial-skin-infections/ The clinical trial investigates the use of oritavancin in treating Acute Bacterial Skin and Skin Structure Infections in children. This infection can appear as wound infections, skin infections with redness and swelling (cellulitis/erysipelas), or collections of pus under the skin (cutaneous abscess). The study will test two forms of the medication – ORBACTIV and KIMYRSA – which are given as a single dose through an intravenous infusion.

The main purpose of this research is to determine if these medications are safe and well-tolerated by children between 3 months and 12 years of age. During the study, children will receive either ORBACTIV or KIMYRSA as a single treatment. Some participants will also receive aztreonam, another antibiotic given by injection.

The study will track how children respond to the treatment and monitor for any side effects. Doctors will check for signs of infection improvement, such as reduction in skin redness, swelling, and warmth. They will also monitor the children’s overall health status throughout the treatment period, which may last up to 14 days.

]]>